Read more: Lies Your Doctor Knows You're Telling Otsuka Pharmaceutical received FDA approval for brexpiprazole, the key ...

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

since 2015. Briefing documents published by the FDA ahead of the meeting also suggested the agency is minded to approve Rexulti for this new use, which analysts have suggested could see a big step ...